|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants.
|
19579870 |
2009 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Rats with STZ-induced diabetes who received GWBR supplementation exhibited decreased expression of sodium-dependent glucose transporter 1 (SGLT1) and glucose transporter (GLUT) 2 genes and proteins in the small intestine via decreases in hepatocyte nuclear factor (HNF)-1α, HNF-1β, and HNF-4α, transcriptional factors that are involved in the regulation of SGLT1 and GLUT2, compared with the rats with STZ-induced diabetes that did not receive GWBR supplements.
|
29093331 |
2017 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The GLUT2 and IRS1 amino acid polymorphisms did not show a simple pattern of co-inheritance with NIDDM in the families of these subjects suggesting that neither polymorphism is sufficient to cause NIDDM but may increase diabetes-susceptibility through their interaction with other loci and environmental factors.
|
7713316 |
1995 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In whole renal tissue, expressions of SGLT2/GLUT2 and SGLT1/GLUT1 are coupled and slightly lower in typical people with T2DM as compared with well-matched people without diabetes.
|
28419670 |
2017 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased α-glucosidase, PEPCK, GLUT-2 and SGLTs levels with the induction of diabetes considerably lowered with TPSE treatment.
|
30399410 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No association between diabetes and the Glut 2 Taq I polymorphism was found in the South Indian subjects.
|
7895459 |
1994 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The disturbance of islet morphology and islet cell contents in diabetes was reduced by the CEE treatment and was associated with a protective effect of CEE on the levels of insulin, GLUT-2 and p-Akt in diabetic islets.
|
31252092 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The change in fasting glucose was assessed in relation to SLC2A2 genotype and glucose-lowering treatment using two-way ANCOVA with gene×treatment interactions adjusted for age, sex, BMI and diabetes duration.
|
30413829 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Administering demethylasterriquinone B1, significantly increased the level of PI3K, AKT phosphorylation and GLUT-2 expression, effectively inhibiting the aggravation of diabetes.
|
29526571 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of GLUT2 transporter by geraniol from Cymbopogon martinii: a novel treatment for diabetes mellitus in streptozotocin-induced diabetic rats.
|
31737917 |
2020 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression of GLUT 2 in Beta cells, but not in hepatocytes, is decreased in diabetes mellitus.
|
1478377 |
1992 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Altered glucose reabsorption <i>via</i> the facilitative glucose transporter 2 (GLUT2) during diabetes may lead to renal proximal tubule cell (RPTC) injury, inflammation, and interstitial fibrosis.
|
29030466 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the analysis of islet GLUT2 in a small sample of human organ donors with and without diabetes raises the possibility that decreased beta-cell GLUT2 may not represent a widespread feature of humans with NIDDM.
|
7589840 |
1995 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Bats: Body mass index, forearm mass index, blood glucose levels and SLC2A2 genes for diabetes.
|
27439361 |
2016 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Four out of five patients with SLC2A2 mutations presented with isolated diabetes and later developed features of FBS.
|
22660720 |
2012 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that the SNPs of SLC2A2 predict the conversion to diabetes in obese subjects with IGT.
|
15983230 |
2005 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In Inter99 two gene variants were associated with risk of CVD independently of diabetes; SLC2A2 (HR 1.180, 95% CI 1.038-1.341 P = 0.0116) and FTO (0.909, 0.827-0.998, P = 0.0463).
|
23185617 |
2012 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in the genes encoding the pancreatic K<sub>ATP</sub> channels can also lead to different types of diabetes (including neonatal diabetes mellitus (NDM) and Maturity Onset Diabetes of the Young, MODY), and defects in the solute carrier family 2 member 2 (<i>SLC2A2</i>) leads to diabetes mellitus as part of the Fanconi-Bickel syndrome.
|
31137773 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We also detected two novel mutations (Val67Met and Leu19Arg) in children with syndromic forms of diabetes like Berardinelli Seip syndrome [1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)] and Fanconi Bickel syndrome [solute carrier family 2A2 (SLC2A2)].
|
22831748 |
2013 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The augmentation of glucose uptake in diabetes is due to the overexpression of renal glucose transporters SGLT-2 and GLUT2 in response to the increase in expression of transcription activator hepatic nuclear factor 1-alpha (HNF1α).
|
25554066 |
2014 |
|
Malabsorption Syndrome
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Glycogen Storage Disease
|
0.040 |
Biomarker
|
group |
BEFREE |
However, complete GLUT2 deficiency in humans leads to hepato-renal glycogenosis (Fanconi-Bickel syndrome), and heterozygous GLUT2 mutations apparently behave in a recessive manner.
|
11485019 |
2001 |
|
Glycogen Storage Disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We have analyzed this family for mutations in the GLUT2 gene and in the three Phk subunit genes that can cause liver glycogenosis (PHKA2, PHKB, and PHKG2).
|
10987651 |
1999 |
|
Glycogen Storage Disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Deleterious variants in SLC2A2 cause Fanconi-Bickel Syndrome (FBS), a glycogen storage disorder, whereas less common variants in SLC2A2 associate with numerous metabolic diseases.
|
30950137 |
2019 |
|
Glycogen Storage Disease
|
0.040 |
Biomarker
|
group |
BEFREE |
GLUT2 dysfunction is associated with several pathologies, including Fanconi-Bickel syndrome, a glycogen storage disease, characterized by growth retardation and renal dysfunction.
|
29218530 |
2018 |